FRONTIER-2: A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis

Ferris LK, et al. J Am Acad Dermatol. 2025 Mar;92(3):495-502

DOWNLOAD PUBLICATION